Open Nav

Please submit your session questions in advance at


  • Patrick(Yang) Lu, Sirnaomics,Inc

Sirnaomics is a clinical stage biopharmaceutical company leveraging an outstanding level of knowledge and experience in RNA interference (RNAi) technology to forge a path to high-value creation through discovery and development of therapeutics for human disorders with unmet medical needs.

  • Date:Monday, February 11
  • Time:11:15 AM - 11:30 AM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23460
  • Goal for Presentation:Seeking Corporation & investment Opportunity
  • Company Website:
  • Company HQ City:Gaithersburg
  • Company HQ State:Maryland
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:70 million
  • CEO/Top Company Official:Patrick Lu
  • Year Founded:2007
  • Main Therapeutic Focus:Multiple Therapeutics
  • Lead Product in Development:STP 705 for Hypertrophic Scar, Liver Cancer & Skin cancer
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):7
  • Additional Information/Comments:The key differentiating feature is the proprietary Polypeptide Nano-Particle (PNP) technology for small interfering RNA (siRNA) drug delivery. This technology allows accessing the tumor micro-environment (TME), as well as various cell types in the liver. The clinical development pipeline is focused on oncology and fibrosis indications. Through the internal research and collaborations with prominent labs at NIH, Johns Hopkins, Duke, University of Maryland and Penn State, Sirnaomics has developed a strong portfolio of intellectual property covering RNAi therapeutic products, key biological mechanisms of action and unique PNP delivery system. The management team collectively has extensive drug development experience, as well as specialized expertise in the areas of oligonucleotide therapeutics and nanoparticle-mediated delivery.
Patrick(Yang) Lu